Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has given approval to Hospira’s Topotecan Injection, a generic version of Hycamtin, indicated for treatment of small cell lung cancer (SCLC) sensitive disease after failure of first-line chemotherapy.
Subscribe to our email newsletter
Hospira, which expects to launch the product by the end of February, said topotecan 4 mg/4 ml is designed to improve caregiver convenience and safety.
Hospira US president Thomas Moore said their solution version of topotecan expands their portfolio of value-added generics.
Hospira, a global specialty pharmaceutical and medication delivery company, offers generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions.